These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21118388)

  • 1. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.
    Dudek MM; Harris LF; Killard AJ
    Int J Lab Hematol; 2011 Jun; 33(3):272-80. PubMed ID: 21118388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time.
    Brandt JT; Triplett DA
    Am J Clin Pathol; 1981 Oct; 76(4 Suppl):530-7. PubMed ID: 7282639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
    Eikelboom JW; Hirsh J
    Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
    Francis JL; Howard C
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.
    Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant.
    Adcock DM; Marlar RA
    Arch Pathol Lab Med; 1992 Aug; 116(8):837-40. PubMed ID: 1497465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental quality assessment of APTT-control reagent kits in the study of heparin-containing plasma in therapeutic ranges].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 Apr; (4):39-41. PubMed ID: 21735680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
    Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
    Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
    Shetty S; Ghosh K; Mohanty D
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
    Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.